NASDAQ:AYTU Aytu BioPharma (AYTU) Stock Price, News & Analysis → Claim Your FREE 'AI Income Playbook' Now! (From The Oxford Club) (Ad) Free AYTU Stock Alerts $2.85 -0.02 (-0.70%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$2.78▼$2.9050-Day Range$2.67▼$3.3652-Week Range$1.38▼$3.50Volume33,068 shsAverage Volume23,646 shsMarket Capitalization$15.87 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Aytu BioPharma alerts: Email Address Aytu BioPharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside75.4% Upside$5.00 Price TargetShort InterestBearish8.65% of Float Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.61 out of 5 starsMedical Sector433rd out of 915 stocksPharmaceutical Preparations Industry191st out of 430 stocks 3.5 Analyst's Opinion Consensus RatingAytu BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAytu BioPharma has received no research coverage in the past 90 days.Read more about Aytu BioPharma's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.65% of the float of Aytu BioPharma has been sold short.Short Interest Ratio / Days to CoverAytu BioPharma has a short interest ratio ("days to cover") of 24, which indicates bearish sentiment.Change versus previous monthShort interest in Aytu BioPharma has recently increased by 10.49%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAytu BioPharma does not currently pay a dividend.Dividend GrowthAytu BioPharma does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAytu BioPharma has received a 39.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Carbinoxamine", "Methylphenidate", and "Amphetamine" products. See details.Environmental SustainabilityThe Environmental Impact score for Aytu BioPharma is -2.45. Previous Next 2.5 News and Social Media Coverage News SentimentAytu BioPharma has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aytu BioPharma this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aytu BioPharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.77% of the stock of Aytu BioPharma is held by insiders.Percentage Held by InstitutionsOnly 33.49% of the stock of Aytu BioPharma is held by institutions.Read more about Aytu BioPharma's insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Aytu BioPharma is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aytu BioPharma is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAytu BioPharma has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aytu BioPharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubClaim Your FREE "AI Income Playbook" Now!Income expert Marc Lichtenfeld has a special gift reserved just for you... It's his brand-new "AI Income Playbook" - and it's yours FREE!Click here now to claim your FREE copy of Marc's AI playbook. About Aytu BioPharma Stock (NASDAQ:AYTU)Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old. The segment also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The Consumer Health segment is involved in the commercialization of over-the-counter medicines, personal care products, and dietary supplements in various categories, such as hair loss, digestive health, urological health, diabetes management, and allergy. The segment offers Regoxidine - for Men and Women, a proprietary over-the-counter aerosol foam that works to treat hair loss in both men and women; and OmepraCareDR and EsomepraCareDR, acid reducers for the treatment of frequent heartburn. It also engages in the development of AR101 (enzastaurin), an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor targeting the treatment of vascular Ehlers-Danlos Syndrome. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Denver, Colorado.Read More AYTU Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AYTU Stock News HeadlinesMay 23, 2024 | finance.yahoo.comAytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 16, 2024 | finance.yahoo.comQ3 2024 Aytu Biopharma Inc Earnings CallMay 16, 2024 | finance.yahoo.comAytu BioPharma Inc (AYTU) Q3 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst ...May 15, 2024 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial ResultsMay 15, 2024 | markets.businessinsider.comHere's what Wall Street expects from Aytu BioPharma's earnings reportApril 17, 2024 | morningstar.comAytu BioPharma Inc 0A8MApril 2, 2024 | msn.comRedHill Biopharma looks to raise $1.25M in a direct offering of securitiesMarch 24, 2024 | morningstar.comAytu BioPharma Inc AYTUMarch 19, 2024 | seekingalpha.comSeelos drops as lead drug fails in ALS trialMarch 18, 2024 | seekingalpha.comSeelos Therapeutics files for 3.4M shares secondary offeringFebruary 25, 2024 | msn.comAytu BioPharma (AYTU) Price Target Increased by 60.00% to 8.16February 16, 2024 | finance.yahoo.comAytu BioPharma Second Quarter 2024 Earnings: Beats ExpectationsFebruary 16, 2024 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call TranscriptFebruary 15, 2024 | finance.yahoo.comQ2 2024 Aytu Biopharma Inc Earnings CallFebruary 14, 2024 | finance.yahoo.comAytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second QuarterFebruary 13, 2024 | benzinga.comEarnings Preview: Aytu BioPharmaFebruary 7, 2024 | finance.yahoo.comAytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024January 23, 2024 | finance.yahoo.comAytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024January 16, 2024 | finance.yahoo.comWhen Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Become Profitable?December 18, 2023 | benzinga.comAytu BioPharma Stock (NASDAQ:AYTU) Dividends: History, Yield and DatesNovember 30, 2023 | finance.yahoo.comAytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023November 15, 2023 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call TranscriptNovember 14, 2023 | finanznachrichten.deAytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2024 First Quarter Financial ResultsNovember 14, 2023 | finance.yahoo.comAytu BioPharma Reports Fiscal 2024 First Quarter Financial ResultsNovember 13, 2023 | markets.businessinsider.comAytu BioPharma earnings: here's what to expectSee More Headlines Receive AYTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/15/2024Fiscal Year End6/30/2024Next Earnings (Estimated)9/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AYTU CUSIPN/A CIK1385818 Webaytubio.com Phone(720) 437-6580FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+75.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,050,000.00 Net Margins-14.60% Pretax Margin-13.45% Return on Equity-31.31% Return on Assets-7.99% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.69 Sales & Book Value Annual Sales$107.40 million Price / Sales0.15 Cash Flow$0.98 per share Price / Cash Flow2.91 Book Value$10.41 per share Price / Book0.27Miscellaneous Outstanding Shares5,570,000Free Float5,414,000Market Cap$15.87 million OptionableNot Optionable Beta-1.31 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Joshua R. Disbrow (Age 49)Chairman & CEO Comp: $708kMr. Mark K. Oki CPA (Age 55)CFO, Secretary & Treasurer Comp: $522.84kMs. Victoria CordovaVice President of People & CultureMr. Jarrett T. Disbrow Ph.D. (Age 49)Chief Business Officer & President of Consumer Health Comp: $355kMr. Russ McMahenSenior Vice President of Research & DevelopmentMr. Ryan J. Selhorn CPA (Age 42)Executive VP of Finance & Business Optimization More ExecutivesKey CompetitorsViveon Health AcquisitionNYSE:VHAQGeneluxNASDAQ:GNLXMediciNovaNASDAQ:MNOVCelularityNASDAQ:CELUHillstream BioPharmaNASDAQ:HILSView All CompetitorsInsidersGreg PyszczymukaBought 12,000 shares on 6/16/2023Total: $22,440.00 ($1.87/share)View All Insider Transactions AYTU Stock Analysis - Frequently Asked Questions Should I buy or sell Aytu BioPharma stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AYTU shares. View AYTU analyst ratings or view top-rated stocks. What is Aytu BioPharma's stock price target for 2024? 1 Wall Street analysts have issued 1-year target prices for Aytu BioPharma's stock. Their AYTU share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price. View analysts price targets for AYTU or view top-rated stocks among Wall Street analysts. How have AYTU shares performed in 2024? Aytu BioPharma's stock was trading at $2.84 at the start of the year. Since then, AYTU stock has increased by 0.4% and is now trading at $2.85. View the best growth stocks for 2024 here. Are investors shorting Aytu BioPharma? Aytu BioPharma saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 463,400 shares, an increase of 10.5% from the May 15th total of 419,400 shares. Based on an average daily volume of 19,300 shares, the days-to-cover ratio is presently 24.0 days. Currently, 8.7% of the company's shares are short sold. View Aytu BioPharma's Short Interest. When is Aytu BioPharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, September 25th 2024. View our AYTU earnings forecast. How were Aytu BioPharma's earnings last quarter? Aytu BioPharma, Inc. (NASDAQ:AYTU) released its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.12. The company had revenue of $17.99 million for the quarter. Aytu BioPharma had a negative trailing twelve-month return on equity of 31.31% and a negative net margin of 14.60%. When did Aytu BioPharma's stock split? Aytu BioPharma's stock reverse split before market open on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Aytu BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX). Who are Aytu BioPharma's major shareholders? Aytu BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Greg Pyszczymuka and Joshua R Disbrow. View institutional ownership trends. How do I buy shares of Aytu BioPharma? Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AYTU) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.